Indicia Production Acquires METIS Biotechnologies
The combined company’s turnover is estimated to reach €8 million ($8.35M) in 2017.
On Jan. 3, 2017 Indicia Production, a contract manufacturer, announced that it will acquire METIS Biotechnologies. METIS develops, produces, and markets rapid microbiological analysis solutions using flow cytometry. Both companies are located in France. The financial terms of the acquisition were not disclosed. Following the acquisition, the consolidated company will operate with 57 employees. Its turnover is estimated to reach €8 million ($8.35M) in 2017, Indicia said.
“The integration of METIS Biotechnologies will strengthen Indicia’s presence on the industrial microbiological control market, in which we have been present since 2008. The technology developed by METIS is now fully operational and meets the needs of the industry,” said Stéphane Legastelois, CEO of Indicia Production in a statement. “In addition, METIS’ know-how in custom solutions will complement our services. This acquisition is part of our strategy to develop through external growth, with a special focus on vertical integration in the field of industrial microbiology.”
Source: Indicia Production
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
